Compare Energy Fuels Inc Ordinary Shares (Canada) (UUUU) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Energy Fuels Inc Ordinary Shares (Canada) vs Vertex Pharmaceuticals Incorporated — how do they compare? Energy Fuels Inc Ordinary Shares (Canada) trades at $8.27 (market cap $2.45B), while Vertex Pharmaceuticals Incorporated trades at $504.96 (market cap $122.98B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 50.2× Energy Fuels Inc Ordinary Shares (Canada)'s market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Energy Fuels Inc Ordinary Shares (Canada) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Energy Fuels Inc Ordinary Shares (Canada) for 0 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| UUUU | VRTX | |
|---|---|---|
Market Cap | $2.45B | $122.98B |
Volume | 7,967,898 | 1,155,743 |
Sector | Energy | Health |
52-Week High | $27.72 | $557.96 |
52-Week Low | $8.34 | $407.90 |
Typical Hold Time | 0 Days | 120 Days |
Enterprise Value | $2.19B | $117.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Energy Fuels (UUUU) trades at $9.27, down 4.04% amid negative sentiment following a securities fraud investigation announcement. The stock shows weak technical positioning near recent lows with neutral indicators. Fundamentally, the company continues to report significant losses with a -77.3% net income margin despite revenue growth projections, while heavy investment in uranium and rare earth expansion creates substantial cash burn.
While analyst consensus remains bullish with a $21.06 price target representing 127% upside, execution risks are elevated. The securities investigation, persistent losses, and massive capital requirements for growth projects create substantial headwinds. Success depends on the company's ability to fund expansion and achieve profitability in the competitive critical minerals sector.
Vertex Pharmaceuticals (VRTX) trades at $498.50, down 1.68% amid mixed technical signals. The stock shows strong fundamentals with $12B revenue, 35% net margins, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Technical indicators show bearish momentum with support at $496 and resistance at $512.
Outlook remains positive with 86% analyst buy ratings and $573.50 price target. Key risks include clinical trial outcomes and competitive pressures. The company's expanding pipeline and profitability provide upside potential, though near-term volatility may persist around key technical levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Energy Fuels Inc Ordinary Shares (Canada)
Energy Fuels Inc. is a US producer of uranium, vanadium, and rare earth elements. It operates the White Mesa Mill in Utah, the only fully licensed and operating conventional uranium processing facility in the country.
Read more on UUUU →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
